Adjuvant FOLFIRINOX Gives Big Boost to Pancreatic Ca Survival
https://www.medpagetoday.com/hematologyoncology/othercancers/77016
https://www.medpagetoday.com/hematologyoncology/othercancers/77016
Dec 19th, 2018 - Patients with pancreatic cancer who underwent adjuvantchemotherapy with modified FOLFIRINOX had a median 20-month overall survival (OS) improvement compared with those treated with gemcitabine, results of the PRODIGE 24 trial found. The improvement of median OS from 35.0 months with gemcitabine to 54.4 months with FOLFIRINOX represents a 36% reduction in the ...
Adjuvant modified FOLFIRINOX improves survival of pancreaticcancer
https://www.mdedge.com/oncologypractice/article/191549/gastroenterology/adjuvant-modified-folfirinox-improves-survival
Neil Osterweil, Oncology Practice
https://www.mdedge.com/oncologypractice/article/191549/gastroenterology/adjuvant-modified-folfirinox-improves-survival
Neil Osterweil, Oncology Practice
Dec 19th, 2018 - For patients with completely or near-completely resected pancreaticductal adenocarcinoma, adjuvant therapy with a modified FOLFIRINOX regimen was associated with significantly better 3-year disease-free survival and overall survival compared with gemcitabine, results of the phase 3 randomized PRODIGE 24 trial showed. At a median follow-up of 33.
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου